AVXL: Anavex Life Sciences Corp. Company Short-Term Debt

Official company branding of Anavex Corp (AVXL)

Anavex Life Sciences (AVXL) focuses on developing advanced treatments for dementia and Parkinson's disease, utilizing sigma-1 receptor stimulation to normalize cellular function. This chart reflecting the price action of a specific short-term debt shows a value of 0.00. The company's financial standing is subject to binary risks due to its dependence on regulatory decisions; however, the potential success of its developments will ensure complete pricing power given the uniqueness of the therapy.

AVXL (Anavex Life Sciences Corp.) Company Short-Term Debts history from 07/04/2022 to 10/31/2026

Summary analytical data breakdowns for Anavex Life Sciences Corp (AVXL)

- current quotes and average value forecast:
Price Chart Anavex Life Sciences Corp.|AVXL - Fair Value Consensus
- market capitalization information:
Market Value Anavex Life Sciences Corp.|AVXL - Total Enterprise Value
- shareholders' equity book value data:
Book Value per Share Anavex Life Sciences|AVXL - Book Capitalization|Market Value to Book Value Ratio anavex.com|AVXL - Total Business Assets
- debt and liquidity details:
Total Debt to Capital Anavex Life Sciences|AVXL - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Anavex Life Sciences|AVXL - Company Debts|Debts to Book Capitalization Anavex Life Sciences Corp.|AVXL - Long-Term Debt|Company Current Liabilities Anavex Life Sciences|Quick Liquidity Indicator anavex.com
- net income and valuation multiples indicators:
AVXL - Final Profit
Fundamental company valuation:Anavex Life Sciences Corp. (AVXL)
Manufactured products of anavex.com

Short-term debt reflects the volume of obligations maturing within one year, measuring the issuer's liquidity and financial stability. An increase in this metric signals a risk of rising interest expenses and a dependence on external refinancing. By analyzing the size of short-term liabilities on GURU.Markets, an investor assesses capital management flexibility. For Anavex Life Sciences (AVXL), this indicator is critical when scaling costly Phase 3 trials. Debt control ensures the stable development of therapies for neurodegenerative diseases.

Main competitors

BIIB - Company Short-Term Debt|Company Short-Term Loans and Borrowings NBIX (Neurocrine)|Regencell (RGC) - Company Short-Term Debt|Short-Term Debt Axsome Corp (AXSM)|ACAD (ACADIA Pharmaceuticals) - Company Short-Term Debts|Company Short-Term Debts xenon-pharma.com|Company Short-Term Debt Viking Therapeutics, Inc. (VKTX)|Supernus Pharmaceuticals, Inc. - Company Short-Term Indebtedness|Company Short-Term Debts CPRX (Catalyst Pharmaceuticals Inc)|Company Short-Term Debts Denali Corp DNLI|HRMY: Company Current Liabilities|BHVN: Company Short-Term Debt|AMLX: Company Short-Term Debts|Short-Term Debt Trevi Therapeutics Inc (TRVI)|Company Current Liabilities PRAX|Company Short-Term Indebtedness CBLL (CeriBell EEG)|Company Current Liabilities PRTA (Prothena)|ALEC (alector.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Annexon ANNX|Omeros Corp - Company Short-Term Debt|Neurogene Corp - Company Short-Term Debts|Short-Term Debt Volume AC Immune Inc ACIU|VYGR: Company Short-Term Debts|Current Liabilities NMRA (neumoratx.com)|SCLX (Scilex) - Company Short-Term Debts|Short-Term Debt Tevogen Bio Holdings Inc. TVGN|Company Current Liabilities ACOG (Alpha Cognition)|CGTX (cogrx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Inhibikase Therapeutics IKT|Short-Term Debt Volume cassavasciences.com (SAVA)|Assertio Therapeutics - Company Short-Term Debts|Coya Therapeutics, Inc. (COYA) - Company Current Liabilities|VTGN: Company Short-Term Debts|OVID - Short-Term Debt Volume|ABOS (Acumen Pharmaceuticals) - Company Short-Term Debts|Short-Term Debt cervomed.com CRVO|Company Short-Term Debt Alterity Therapeutics (ATHE)|clene.com - Company Short-Term Indebtedness|Company Short-Term Debts PEPG (PepGen)|JUNS - Company Current Liabilities|Relmada Therapeutics - Company Short-Term Debts|Short-Term Debt annovisbio.com|gracetx.com (GRCE) - Company Short-Term Debt|AIFF - Short-Term Debt Volume|KLTO (ANEW Medical) - Company Short-Term Debts|Company Short-Term Debts NeuroSense Therapeutics, Ltd.|Company Current Liabilities RVPH (Reviva Pharmaceuticals)|Company Short-Term Debt MTVA (metaviatx.com)|NeurAxis - Company Current Liabilities|HSDT: Company Short-Term Indebtedness|PASG - Company Short-Term Debt|NEUP: Company Short-Term Debt|Minerva Neurosciences (NERV) - Company Short-Term Debt|Company Short-Term Indebtedness ATHA|ADXN (Addex Therapeutics Ltd) - Company Short-Term Debts|Short-Term Debt Alzamend ALZN|Company Current Liabilities CYCN (Cyclerion Therapeutics)|Company Short-Term Debts protagenic.com (PTIX)|Company Short-Term Debt Pasithea Therapeutics Corp. KTTA|Company Short-Term Loans and Borrowings CRGT|ATXI - Company Short-Term Debt|Short-Term Debt Brainstorm Cell Therapeutics Inc.|CARA: Company Short-Term Debts|Chromocell (CHRO) - Company Short-Term Debts|Company Short-Term Debt Eliem Therapeutics, Inc.|Company Short-Term Indebtedness ITCI (Intra-Cellular)|Company Short-Term Debts LBPH|Company Short-Term Debts Marinus Pharmaceuticals Inc (MRNS)|NKGen - Company Current Liabilities|NeuroBo Pharma - Company Short-Term Debt|Sage Therapeutics, Inc. - Company Short-Term Debts|Short-Term Debt synaptogen.com|TRVN (Trevena) - Company Current Liabilities|Company Short-Term Indebtedness VIGL|Company Current Liabilities WENA|CERE: Company Short-Term Loans and Borrowings